EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Histological evaluation of clinically defined atrial cardiomyopathy stages and their association with atrial fibrillation burden under continuous monitoring for a 2.5-year follow-up

Joris Winters iD, Michal Kawczynski iD, Martijn Gilbers iD, Aaron Isaacs iD, Stef Zeemering iD, Zarina Habibi iD, Michiel Rienstra iD, Isabelle van Gelder iD, Bart Maesen iD, Elham Bidar iD, Sander Verheule iD, Ulrich Schotten iD

Europace · 2026

DOI: 10.1093/europace/euag146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Europace, 2026. Verfasst von Joris Winters und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Cardiovascular Research Institute Maastricht, University Maastricht, Maastricht, the Netherlands. Hauptthemen laut MEDLINE: Atrial Fibrillation, Heart Atria, Cardiomyopathies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Netherlands Heart Foundation, RACE V Reappraisal of Atrial Fibrillation, EmbRACE.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Atrial cardiomyopathy (AtCM) is associated with atrial fibrillation (AF). While histological studies describe underlying mechanisms of AtCM, these insights remain disconnected from clinical AtCM. This study determines the histological basis of non-invasive AtCM markers and assess their prognostic value in patients undergoing cardiac surgery. Methods and results Left and right (LA/RA) atrial tissue samples were obtained in patients undergoing cardiac surgery (n = 136) in the RACE V Tissue Bank study. Pre-operative rhythm history, digital ECG, transthoracic echocardiography (TTE) and biomarker levels were used to group patients in AtCM stages: AF: history of paroxysmal, persistent or permanent AF, Severe (LAVi>50 mL/m2 or LAEF<35%), Moderate (LAVi 34–50 mL/m2, or LAEF 35–50% AND NT-proBNP >250 pg/mL), Mild (no AF, LAVi≤34 mL/m2 AND P-terminal Force V1 > 5 mV*ms OR P wave duration > 120 ms), and no AtCM. Tissue was stained (WGA/CD31/Vimentin) to quantify fibrosis, fibroblast density, myocyte diameter and vascularization. Post-operative rhythm was monitored continuously (2.5 years) using implantable loop recorders. Patients with severe AtCM had extended endomysial fibrosis (LA: +0.82µm, pFDR,LA < 0.001; RA: +0.64µm, pFDR,RA = 0.010) and larger left atrial cardiomyocytes (LA: +0.92µm, pFDR,LA = 0.026). Moderate AtCM patients showed LA myocyte hypertrophy (LA: +1.35µm, pFDR,LA = 0.007). Mild AtCM patients had similar histological features to patients without AtCM. Moderate (β = 3.56, pFDR = 0.045) and severe (β = 3.74, pFDR = 0.034) AtCM patients had a higher AF burden late after cardiac surgery. Conclusion Clinical AtCM markers reflect pro-fibrotic and pro-hypertrophic remodelling in the moderate to severe AtCM stages and are associated with a higher AF burden late after surgery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationHeart AtriaCardiomyopathiesHumansFemaleMaleAgedBiomarkersMiddle AgedFibrosisFollow-Up StudiesEchocardiographyTime FactorsPredictive Value of TestsAtrial RemodelingElectrocardiographyPrognosisNatriuretic Peptide, BrainSeverity of Illness Index

Stichwörter der Autor:innen

AF burdenAtrial cardiomyopathyAtrial fibrillationBiomarkersFibrosisMyocyte hypertrophy

Substanzen

BiomarkersNatriuretic Peptide, Brain

Autor:innen und Institutionen

  • Department of Physiology, Cardiovascular Research Institute Maastricht, University Maastricht, Maastricht, the Netherlands.
  • Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Cardiothoracic Surgery, Maastricht University Medical Centre+, PO Box 616, Maastricht 6200 MD, the Netherlands.
  • Maastricht Centre for Systems Biology and Bioinformatics, University Maastricht, Maastricht, the Netherlands.
  • Department of Cardiology, University Medical Centre Groningen, Groningen, the Netherlands.

ORCID-Profile: Joris Winters, Michal Kawczynski, Martijn Gilbers, Aaron Isaacs, Stef Zeemering, Zarina Habibi, Michiel Rienstra, Isabelle van Gelder, Bart Maesen, Elham Bidar, Sander Verheule, Ulrich Schotten

Förderung

  • Netherlands Heart Foundation
  • RACE V Reappraisal of Atrial Fibrillation
  • EmbRACE
  • European Union
  • CATCH ME
  • MAESTRIA

Zitieren

APA

Winters, J., Kawczynski, M., Gilbers, M., Isaacs, A., Zeemering, S., Habibi, Z., Rienstra, M., van Gelder, I., Maesen, B., Bidar, E., Verheule, S., & Schotten, U. (2026). Histological evaluation of clinically defined atrial cardiomyopathy stages and their association with atrial fibrillation burden under continuous monitoring for a 2.5-year follow-up. Europace. https://doi.org/10.1093/europace/euag146

Vancouver

Winters J, Kawczynski M, Gilbers M, Isaacs A, Zeemering S, Habibi Z, et al. Histological evaluation of clinically defined atrial cardiomyopathy stages and their association with atrial fibrillation burden under continuous monitoring for a 2.5-year follow-up. Europace. 2026. doi:10.1093/europace/euag146

BibTeX
@article{Winters2026,
  author = {Winters, Joris and Kawczynski, Michal and Gilbers, Martijn and Isaacs, Aaron and Zeemering, Stef and Habibi, Zarina and Rienstra, Michiel and van Gelder, Isabelle and Maesen, Bart and Bidar, Elham and Verheule, Sander and Schotten, Ulrich},
  title = {Histological evaluation of clinically defined atrial cardiomyopathy stages and their association with atrial fibrillation burden under continuous monitoring for a 2.5-year follow-up},
  journal = {Europace},
  year = {2026},
  doi = {10.1093/europace/euag146}
}
Kostenlos starten →